Navigation Links
Intellikine Appoints William Rohn to its Board of Directors
Date:2/23/2010

LA JOLLA, Calif., Feb. 23 /PRNewswire/ -- Intellikine, Inc., a leader in the development of drugs against the PI3K/mTOR pathway, today announced that William R. Rohn has joined the company's board of directors.

Mr. Rohn has over 30 years of management experience in the biotechnology and pharmaceutical industry, including more than 10 years in executive management positions at IDEC Pharmaceuticals and Biogen Idec, where he served as Chief Operating Officer until his retirement in 2005.  He joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development, was appointed Senior Vice President, Commercial Operations and was promoted to Chief Operating Officer in 1998. In 2002, he became President, responsible for Sales, Marketing, Business Development, Manufacturing, Quality, Medical Affairs and CMC Regulatory Affairs.  He was responsible for building IDEC's commercial infrastructure to support the launch of Rituxan, the first monoclonal antibody approved in the U.S. for the treatment of cancer.  Mr. Rohn serves on the boards of directors of Elan Corporation, plc, Cerus Corporation, and Cebix, Inc.

"We are delighted to welcome Bill Rohn to Intellikine's board of directors," said Troy Wilson, Ph.D., J.D., President and CEO of Intellikine.  "His strategic insights and experience in growing biotechnology companies, including his experience transitioning IDEC from a development stage company to a very successful commercial enterprise, will be invaluable to Intellikine as we seek to advance our growing pipeline of drugs against the PI3K/mTOR pathway."

"Intellikine has rapidly built one of the best pipelines against the PI3K/mTOR pathway," said William Rohn.  "I am excited about the opportunity to work with the management team and board to build the company and, in particular, to forge industry-leading partnerships to develop and commercialize the company's products for the treatment of cancer, inflammation and other serious diseases."

About Intellikine

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway.  Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseases.  Other programs include PI3K-delta/gamma dual-selective inhibitors for oncology, PI3K-alpha/beta selective inhibitors for oncology, as well as other isoform-selective inhibitors. Intellikine has raised $41 million from an outstanding group of life science investors including Abingworth, Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, U.S. Venture Partners, Biogen Idec and FinTech Global Capital.  In addition, Intellikine has a commitment, subject to fulfillment of certain conditions, for another $22.5 million in equity financing from its current investors.  For more information, please visit the company's website at www.intellikine.com.

SOURCE Intellikine, Inc.

Back to top

RELATED LINKS
http://www.intellikine.com

'/>"/>

SOURCE Intellikine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations
2. TechTeam Global Appoints Life Sciences Services Director
3. ADVENTRX Appoints Icahn Representative to Board of Directors
4. MS&L Appoints Patricia Archambault as Vice President, Healthcare in Montreal
5. Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board
6. Avantium Appoints Gunnar Staaf as CEO Pharma
7. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
8. Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility
9. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
10. Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer
11. Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):